Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Yoshio, Kurihara"'
Autor:
Ken‐ichi Tsuchida, Shinji Taneda, Isao Yokota, Kazufumi Okada, Yoshio Kurihara, Hiroki Yokoyama, Masahiro Iwamoto, Katsuya Yamazaki, Yasushi Ishigaki, Naoki Manda, Hiroshi Maegawa, Japan Diabetes Clinical Data Management Study Group (JDDM study group)
Publikováno v:
Journal of Diabetes Investigation, Vol 13, Iss 11, Pp 1834-1841 (2022)
ABSTRACT Aims/Introduction Few studies have investigated the renoprotective effect of glucagon‐like peptide‐1 (GLP‐1) receptor in patients with chronic kidney disease (CKD). This study evaluated the effect of dulaglutide 0.75 mg on renal functi
Externí odkaz:
https://doaj.org/article/d55ac9c50b4e454eabde6b1f67ff136e
Autor:
Aika Miya, Akinobu Nakamura, Kyu Yong Cho, Shinichiro Kawata, Hiroshi Nomoto, So Nagai, Hajime Sugawara, Shinji Taneda, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama, Jun Takeuchi, Shin Aoki, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyoshi
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 8, Pp 1395-1399 (2021)
Abstract Aims/Introduction To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucos
Externí odkaz:
https://doaj.org/article/2ade46145c304a1cb4788ecbd261113a
Autor:
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuno Omori, Kazuhisa Tsuchida, Aika Miya, Ikumi Shigesawa, Kenichi Tsuchida, Shingo Yanagiya, Hiraku Kameda, Hiroki Yokoyama, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Naoki Nishimoto, Tatsuya Atsumi, Hideaki Miyoshi
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 8, Pp 1417-1424 (2021)
Abstract Aims/Introduction We recently reported the beneficial effect of the combination of sodium–glucose cotransporter 2 inhibitor and dipeptidyl peptidase‐4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus. Add
Externí odkaz:
https://doaj.org/article/3e8bdc46ba6e43f5ae3287bfe8db2f38
Autor:
Kyu Yong Cho, Akinobu Nakamura, Kazuno Omori, Takahiro Takase, Aika Miya, Kohei Yamamoto, Hiroshi Nomoto, Hiraku Kameda, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 7, Pp 1272-1277 (2021)
Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compar
Externí odkaz:
https://doaj.org/article/ffadb1ffdf4c4d3d9a134f5dc545c62d
Autor:
Hiroshi Hayashi, Mariko Oishi, Hiroki Yokoyama, Shin-ichi Araki, Koichi Kawai, Katsuya Yamazaki, Osamu Tomonaga, Shin-ichiro Shirabe, Hiroshi Maegawa, Miyoko Saito, Yoshio Kurihara, Takeshi Osonoi, Daijiro Kabata, Ayumi Shintani, Hiroshi Yamaguchi, Masahiro Iwamoto, Haruhiko Yoshimura, Yasushi Ishigaki, Yoshihiko Takahashi, Hiroshi Takamura, Daigaku Uchida, Atsunori Kashiwagi, Masae Minami, Hiroshi Takeda, Akira Kanamori, Akiko Hosokawa, Azuma Kanatsuka, Noriharu Yagi, Atsushi Hasegawa, Masakazu Kato, Naoki Manda, Kazuhiro Miyazawa, Tetsuya Moriai, Kenichi Tsuchida, Daishiro Yamada, Makoto Nakazono, Fuminobu Okuguchi, Takashi Ajihara, Shigetake Ko, Susumu Nakamura, Akira Tsuruoka, Mitsutoshi Kato, Akio Ueki, Koichi Hirao, Kotaro Iemitsu, Hajime Maeda, Masahiko Takai, Masato Takaki, Hikari Suzuki, Yuki Kono, Sumio Kato, Ituko Miyazawa, Takashi Noto, Koichi Iwasaki, Hiroshi Ninomiya, Kokichi Tanaka, Yoshifumi Yokomizo, Kohei Yamaguchi, Katsushige Abe, Nobuyuki Abe, Nobuki Yano, Michiko Chosa, Takako Arakaki
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 10, Iss 3 (2022)
Externí odkaz:
https://doaj.org/article/3a3b6c618a2146ec95286df435ad7085
Autor:
Kyu Yong Cho, Hiroki Yokoyama, Tatsuya Atsumi, Hiroshi Nomoto, Jun Takeuchi, So Nagai, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Hideaki Miyoshi, Shinji Taneda, Ichiro Sakuma, Sho Furusawa, Aika Miya, Hiraku Kameda
Publikováno v:
BMJ Open, Vol 12, Iss 5 (2022)
Introduction Incretin-based therapies exert antihyperglycaemic effects in patients with type 2 diabetes (T2D) in a blood glucose concentration-dependent fashion. The first-in-class oral glucagon-like peptide-1 receptor agonist semaglutide has potent
Externí odkaz:
https://doaj.org/article/c71ac11459cd403d8e49e781e78fd724
Autor:
Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 2, Pp 176-183 (2021)
Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in p
Externí odkaz:
https://doaj.org/article/1dbe280944994136a7b013586e954b51
Autor:
Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Publikováno v:
Diabetes & Metabolism Journal, Vol 44, Iss 4, Pp 532-541 (2020)
BackgroundTo explore the efficacy and safety of switching from once-daily basal insulin therapy to once-daily pre-meal injection insulin degludec/insulin aspart (IDegAsp) with respect to the glycemic control of participants with type 2 diabetes melli
Externí odkaz:
https://doaj.org/article/0405fcef939e4d59869fb1b6eeeddd9c
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 12, Iss 1, Pp 1-6 (2020)
Abstract Background We compared the effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease (CKD) classified by degree of albuminuria. Methods A retrospective re
Externí odkaz:
https://doaj.org/article/0a905d94c4bf468f8e6d5d5dc9f3bdef
Publikováno v:
Journal of Diabetes Investigation, Vol 10, Iss 6, Pp 1510-1517 (2019)
Abstract Aims/Introduction The risk of end‐stage kidney disease increases in proportion to the decline in the estimated glomerular filtration rate (eGFR). Although protective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on the eG
Externí odkaz:
https://doaj.org/article/8d7b756f6b7e40d3930a4bdaec908fb7